Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yingli Reports Positive Data from Phase III Trial of Linperlisib for T-cell Lymphoma

publication date: Dec 11, 2023

Shanghai Yingli Pharma reported positive data from a pivotal Phase II trial of linperlisib in patients with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL). Linperlisib is an oral phosphoinositide 3-kinase delta (PI3Kδ) inhibitor that is already approved in China for patients with r/r follicular lymphoma after systemic therapy. Based on the study’s findings, the company has applied for linperlisib marketing approval in China for r/r PTCL. In 2021, the company formed a collaboration that granted Hengrui Medicine joint development rights to linperlisib in China in exchange for a $20 million investment in Yingli. More details.....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital